Synapse - Mark Robson

Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making

Journal Article

Abida, W.; Armenia, J.; Gopalan, A.; Brennan, R.; Walsh, M.; Barron, D.; Danila, D.; Rathkopf, D.; Morris, M.; Slovin, S.; more...
JCO Precision Oncology (2017)

Fulltext@MSK | Save

Decision-making preferences about secondary germline findings that arise from tumor genomic profiling among patients with advanced cancers

Journal Article

Hamilton, J. G.; Shuk, E.; Garzon, M. G.; Rodríguez, V. M.; Westerman, J.; Hay, J. L.; Offit, K.; Robson, M. E.
JCO Precision Oncology (2017)

Fulltext@MSK | Save

Determining the prevalence of germline BAP1 mutations in malignant mesothelioma (MM)

Meeting Abstract

Zauderer, M. G.; DuBoff, M. A.; Siegel, B.; Robson, M. E.; Arnold, A. G.; Berliner, J.; Fleischut, M. H.; Mandelker, D.; Ladanyi, M.
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO)

Meeting Abstract

Turner, N. C.; Telli, M. L.; Rugo, H. S.; Mailliez, A.; Ettl, J.; Grischke, E. M.; Mina, L. A.; Gelpi, J. B.; Fasching, P. A.; Hurvitz, S. A.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)